1. Home
  2. CBIO vs HAIN Comparison

CBIO vs HAIN Comparison

Compare CBIO & HAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • HAIN
  • Stock Information
  • Founded
  • CBIO 2003
  • HAIN 1993
  • Country
  • CBIO United States
  • HAIN United States
  • Employees
  • CBIO N/A
  • HAIN N/A
  • Industry
  • CBIO
  • HAIN Packaged Foods
  • Sector
  • CBIO
  • HAIN Consumer Staples
  • Exchange
  • CBIO Nasdaq
  • HAIN Nasdaq
  • Market Cap
  • CBIO 173.5M
  • HAIN 140.9M
  • IPO Year
  • CBIO N/A
  • HAIN 1993
  • Fundamental
  • Price
  • CBIO $10.13
  • HAIN $1.34
  • Analyst Decision
  • CBIO Strong Buy
  • HAIN Hold
  • Analyst Count
  • CBIO 5
  • HAIN 10
  • Target Price
  • CBIO $25.60
  • HAIN $3.48
  • AVG Volume (30 Days)
  • CBIO 127.5K
  • HAIN 2.1M
  • Earning Date
  • CBIO 11-23-2025
  • HAIN 11-06-2025
  • Dividend Yield
  • CBIO N/A
  • HAIN N/A
  • EPS Growth
  • CBIO N/A
  • HAIN N/A
  • EPS
  • CBIO N/A
  • HAIN N/A
  • Revenue
  • CBIO N/A
  • HAIN $1,559,780,000.00
  • Revenue This Year
  • CBIO N/A
  • HAIN N/A
  • Revenue Next Year
  • CBIO N/A
  • HAIN $0.91
  • P/E Ratio
  • CBIO N/A
  • HAIN N/A
  • Revenue Growth
  • CBIO N/A
  • HAIN N/A
  • 52 Week Low
  • CBIO $10.13
  • HAIN $1.30
  • 52 Week High
  • CBIO $21.40
  • HAIN $9.43
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 31.99
  • HAIN 31.56
  • Support Level
  • CBIO $10.96
  • HAIN $1.50
  • Resistance Level
  • CBIO $12.58
  • HAIN $1.47
  • Average True Range (ATR)
  • CBIO 0.74
  • HAIN 0.08
  • MACD
  • CBIO -0.10
  • HAIN -0.02
  • Stochastic Oscillator
  • CBIO 4.27
  • HAIN 7.89

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About HAIN Hain Celestial Group Inc. (The)

The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.

Share on Social Networks: